Stock CTNM CONTINEUM THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Contineum Therapeutics, Inc.

Equities

CTNM

US21217B1008

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-17 pm EDT 		5-day change 1st Jan Change
15.5 USD +3.61% Intraday chart for Contineum Therapeutics, Inc. -1.96% 0.00%
Apr. 30 Morgan Stanley Starts Contineum Therapeutics With Overweight Rating MT
Apr. 30 Stifel Starts Contineum Therapeutics With Buy Rating, $29 Price Target MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
BU
Morgan Stanley Starts Contineum Therapeutics With Overweight Rating
MT
Stifel Starts Contineum Therapeutics With Buy Rating, $29 Price Target
MT
RBC Initiates Contineum Therapeutics at Outperform, Speculative Risk With $30 Price Target
MT
Contineum Therapeutics, Inc.(NasdaqGS:CTNM) added to NASDAQ Composite Index
CI
Sector Update: Health Care Stocks Rise Late Afternoon
MT
Sector Update: Health Care
MT
Contineum Therapeutics' Shares Fall After IPO Pricing
MT
Contineum Therapeutics Prices IPO at $16 a Share
MT
Contineum Therapeutics Announces Pricing of Initial Public Offering
AQ
Contineum Therapeutics, Inc. has completed an IPO in the amount of $110 million.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CTNM Stock
  4. News Contineum Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW